T Cell News and Research

Latest T Cell News and Research

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

Physicians offer several promising and unique approaches to brain tumor treatment

An estimated 41,000 new cases of primary brain tumors are expected to be diagnosed in 2004, according to the American Brain Tumor Association.

5 Aug 2004

First evidence of the molecular link between inflammation and cancer

The investigators found that a gene called I-kappa-B kinase (IKK beta), a pro-inflammatory gene, acts differently in two cell types to cause cancer. When IKK beta was deleted, the cancer incidence and tumor growth in mice was decreased by nearly 80 percent.

5 Aug 2004

New gene-silencing technique

A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.

5 Aug 2004

Experimental vaccine against ricin

Scientists have developed an experimental vaccine against ricin, a potential biological threat agent, which fully protected mice from aerosol challenge with lethal doses of the toxin.

5 Aug 2004

Protein loss plays role in acute T-cell leukemia

The loss of a key protein (Smad3) in a pathway that helps prevent tumors from forming is specific to one form of childhood leukemia, but not to other pediatric and adult forms of leukemia, according to a new study published in the August 5, 2004, New England Journal of Medicine.

5 Aug 2004

New screening test for oesophageal (food pipe) cancer

A new screening test for oesophageal (food pipe) cancer could dramatically improve survival from the disease, according to research published in the British Journal of Cancer this week.

5 Aug 2004

Smart drug that targets cancer cells in the brain following removal of a tumor

The use of a "smart" drug that targets cancer cells in the brain following removal of a tumor may provide treatment that can extend the survival of people with the most common form of primary malignant brain tumor, glioblastoma multiforme (GBM).

3 Aug 2004

Successfully cloning mice from an advanced melanoma cell

Nature can reset the clock in certain types of cancer and reverse many of the elements responsible for causing malignancy, reports a research team led by Whitehead Institute Member Rudolf Jaenisch, in collaboration with Lynda Chin from Dana Farber Cancer Institute.

3 Aug 2004

FDA has granted orphan drug designation to Myogen's ambrisentan, for the treatment of pulmonary arterial hypertension

Myogen has announced that the United States Food and Drug Administration has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH).

3 Aug 2004

New Drug Application with the U.S. Food and Drug Administration for Tarceva

OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),

3 Aug 2004

New screening technique to look for genes that change patients' responses to cancer drugs and other medications

Scientists have developed a new screening technique to help them look for genes that change patients' responses to cancer drugs and other medications.

3 Aug 2004

One-third of U.S. adults use some form of alternative medicine

More than one-third of U.S. adults use some form of alternative medicine such as herbal supplements and other therapies, showed in a nationwide survey by NIH's National Center for Complementary and Alternative Medicine published in May 2004.

2 Aug 2004

Antioxidant pills do nothing to prevent cardiovascular disease

Research published in the current issue of the Journal of the American Heart Association, shows that antioxidant pills have no clear benefit in the prevention of cardiovascular disease.

2 Aug 2004

First-of-its-kind noninvasive imaging technique shows two proteins interacting

Radiologists at Washington University School of Medicine in St. Louis have developed a first-of-its-kind noninvasive imaging technique that allows them to watch two proteins interacting in live animals.

2 Aug 2004

New approach to cancer vaccines may eradicate skin cancer tumors

Mayo Clinic and British researchers have developed a new approach to cancer vaccines that purposely kills healthy skin cells to target the immune system against tumors. The new approach has eradicated skin cancer tumors in mice.

2 Aug 2004

Scientists create mice that don't gain weight, even when fed fat-laden, high calorie diets

By altering the expression of a single -- albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.

2 Aug 2004

Hormone that is important in the control of blood pressure may also inhibit the growth of lung cancer cells

Their studies found that angiotensin-(1-7) significantly slows the growth of three different types of human lung cancer cells in the laboratory. "Our experiments provide the first evidence that angiotensin-(1-7) inhibits the proliferation of human lung cancer cells," they said.

2 Aug 2004

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Researchers in New York City and Guangzhou, China applied the rapidly-developing carbohydrate microarray technology to study an inactivated SARS-coronavirus (SARS-CoV) vaccine and discovered autoimmunogenic activity of this newly identified human viral pathogen.

2 Aug 2004

The p53 transcription factor plays a vital role in preventing cancer onset

Researchers at the Uppsala Branch of the Ludwig Institute for Cancer Research have discovered that the transcription factor Yin Yang 1 (YY1) is a novel regulator of the tumor suppressor p53, which is inactivated in at least half of all human cancers.

2 Aug 2004